NO330508B1 - Blanding bestaende av syntetisk fosfodiester-nukleotidsekvens og anvendelse derav. - Google Patents

Blanding bestaende av syntetisk fosfodiester-nukleotidsekvens og anvendelse derav. Download PDF

Info

Publication number: NO330508B1
Authority: NO; Norway
Prior art keywords: cells; base; seq; sequences; cancer
Prior art date: 1999-12-13

Application number

NO20022820A

Other languages

English (en)

Norwegian (no)

Other versions

NO20022820L (no

NO20022820D0 (no

Inventor

Nigel C Phillips

Mario C Filion

Original Assignee

Bioniche Life Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-13

Filing date

2002-06-13

Publication date

2011-05-09

2002-06-13 Application filed by Bioniche Life Sciences Inc filed Critical Bioniche Life Sciences Inc

2002-06-13 Publication of NO20022820D0 publication Critical patent/NO20022820D0/no

2002-08-08 Publication of NO20022820L publication Critical patent/NO20022820L/no

2011-05-09 Publication of NO330508B1 publication Critical patent/NO330508B1/no

Links

239000000203 mixture Substances 0.000 title claims abstract description 21
239000002773 nucleotide Substances 0.000 title claims abstract description 6
206010028980 Neoplasm Diseases 0.000 claims abstract description 74
201000011510 cancer Diseases 0.000 claims abstract description 46
102000011727 Caspases Human genes 0.000 claims abstract description 30
108010076667 Caspases Proteins 0.000 claims abstract description 30
230000004913 activation Effects 0.000 claims abstract description 30
230000035755 proliferation Effects 0.000 claims abstract description 26
230000005764 inhibitory process Effects 0.000 claims abstract description 25
238000004519 manufacturing process Methods 0.000 claims abstract description 22
230000025084 cell cycle arrest Effects 0.000 claims abstract description 16
102000004127 Cytokines Human genes 0.000 claims abstract description 15
108090000695 Cytokines Proteins 0.000 claims abstract description 15
230000006698 induction Effects 0.000 claims abstract description 13
230000006882 induction of apoptosis Effects 0.000 claims abstract description 9
239000003937 drug carrier Substances 0.000 claims abstract description 8
210000000987 immune system Anatomy 0.000 claims abstract description 8
230000004044 response Effects 0.000 claims abstract description 5
102000013462 Interleukin-12 Human genes 0.000 claims description 23
108010065805 Interleukin-12 Proteins 0.000 claims description 23
208000032839 leukemia Diseases 0.000 claims description 23
102000004889 Interleukin-6 Human genes 0.000 claims description 15
108090001005 Interleukin-6 Proteins 0.000 claims description 15
239000002246 antineoplastic agent Substances 0.000 claims description 14
239000003814 drug Substances 0.000 claims description 13
208000026310 Breast neoplasm Diseases 0.000 claims description 12
206010006187 Breast cancer Diseases 0.000 claims description 11
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 11
229940127089 cytotoxic agent Drugs 0.000 claims description 11
102000003814 Interleukin-10 Human genes 0.000 claims description 10
108090000174 Interleukin-10 Proteins 0.000 claims description 10
206010060862 Prostate cancer Diseases 0.000 claims description 9
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 9
238000011282 treatment Methods 0.000 claims description 9
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 8
206010009944 Colon cancer Diseases 0.000 claims description 8
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 8
229940079593 drug Drugs 0.000 claims description 8
206010033128 Ovarian cancer Diseases 0.000 claims description 7
206010061535 Ovarian neoplasm Diseases 0.000 claims description 7
102000003777 Interleukin-1 beta Human genes 0.000 claims description 6
108090000193 Interleukin-1 beta Proteins 0.000 claims description 6
206010025323 Lymphomas Diseases 0.000 claims description 6
208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
206010039491 Sarcoma Diseases 0.000 claims description 5
206010027476 Metastases Diseases 0.000 claims description 4
230000000340 anti-metabolite Effects 0.000 claims description 4
229940100197 antimetabolite Drugs 0.000 claims description 4
239000002256 antimetabolite Substances 0.000 claims description 4
229940100198 alkylating agent Drugs 0.000 claims description 3
239000002168 alkylating agent Substances 0.000 claims description 3
210000000481 breast Anatomy 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 3
208000011646 secondary carcinoma Diseases 0.000 claims description 3
206010005949 Bone cancer Diseases 0.000 claims description 2
208000018084 Bone neoplasm Diseases 0.000 claims description 2
201000009030 Carcinoma Diseases 0.000 claims description 2
239000003667 hormone antagonist Substances 0.000 claims description 2
230000002611 ovarian Effects 0.000 claims description 2
210000002307 prostate Anatomy 0.000 claims description 2
210000004027 cell Anatomy 0.000 description 145
241000699670 Mus sp. Species 0.000 description 44
210000001744 T-lymphocyte Anatomy 0.000 description 34
230000006907 apoptotic process Effects 0.000 description 26
108090000397 Caspase 3 Proteins 0.000 description 25
102100029855 Caspase-3 Human genes 0.000 description 22
230000000694 effects Effects 0.000 description 18
230000004663 cell proliferation Effects 0.000 description 17
239000003795 chemical substances by application Substances 0.000 description 15
150000004713 phosphodiesters Chemical class 0.000 description 15
108090000567 Caspase 7 Proteins 0.000 description 14
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 14
102100038902 Caspase-7 Human genes 0.000 description 13
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 13
241001529936 Murinae Species 0.000 description 12
241001467552 Mycobacterium bovis BCG Species 0.000 description 12
229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 12
230000022131 cell cycle Effects 0.000 description 11
102000008297 Nuclear Matrix-Associated Proteins Human genes 0.000 description 10
108010035916 Nuclear Matrix-Associated Proteins Proteins 0.000 description 10
230000006052 T cell proliferation Effects 0.000 description 10
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
230000009702 cancer cell proliferation Effects 0.000 description 9
229960002949 fluorouracil Drugs 0.000 description 9
230000002401 inhibitory effect Effects 0.000 description 9
238000000034 method Methods 0.000 description 9
108090000623 proteins and genes Proteins 0.000 description 9
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 8
235000018102 proteins Nutrition 0.000 description 8
102000004169 proteins and genes Human genes 0.000 description 8
239000011780 sodium chloride Substances 0.000 description 8
206010000871 Acute monocytic leukaemia Diseases 0.000 description 7
241000282465 Canis Species 0.000 description 7
208000035489 Monocytic Acute Leukemia Diseases 0.000 description 7
108091034117 Oligonucleotide Proteins 0.000 description 7
239000011575 calcium Substances 0.000 description 7
239000000969 carrier Substances 0.000 description 7
238000003776 cleavage reaction Methods 0.000 description 7
230000007017 scission Effects 0.000 description 7
229960001603 tamoxifen Drugs 0.000 description 7
108020004414 DNA Proteins 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
230000000118 anti-neoplastic effect Effects 0.000 description 6
210000003719 b-lymphocyte Anatomy 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
239000000839 emulsion Substances 0.000 description 6
238000012545 processing Methods 0.000 description 6
239000007787 solid Substances 0.000 description 6
239000000725 suspension Substances 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
208000000389 T-cell leukemia Diseases 0.000 description 5
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 5
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 5
230000001093 anti-cancer Effects 0.000 description 5
239000000872 buffer Substances 0.000 description 5
230000016396 cytokine production Effects 0.000 description 5
238000000684 flow cytometry Methods 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
230000035800 maturation Effects 0.000 description 5
239000012528 membrane Substances 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
229940124597 therapeutic agent Drugs 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
OZLGRUXZXMRXGP-UHFFFAOYSA-N Fluo-3 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(Cl)C(=O)C=C3OC3=CC(O)=C(Cl)C=C32)N(CC(O)=O)CC(O)=O)=C1 OZLGRUXZXMRXGP-UHFFFAOYSA-N 0.000 description 4
230000018199 S phase Effects 0.000 description 4
239000006180 TBST buffer Substances 0.000 description 4
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
230000003321 amplification Effects 0.000 description 4
239000008365 aqueous carrier Substances 0.000 description 4
125000004429 atom Chemical group 0.000 description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
230000030833 cell death Effects 0.000 description 4
210000000170 cell membrane Anatomy 0.000 description 4
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
229960004316 cisplatin Drugs 0.000 description 4
230000000295 complement effect Effects 0.000 description 4
-1 growth-inhibiting Proteins 0.000 description 4
238000003199 nucleic acid amplification method Methods 0.000 description 4
229910052760 oxygen Inorganic materials 0.000 description 4
239000001301 oxygen Substances 0.000 description 4
125000004430 oxygen atom Chemical group O* 0.000 description 4
230000009467 reduction Effects 0.000 description 4
SUEGWIXYCHISPX-UHFFFAOYSA-N sulfane trihydroxy(sulfanylidene)-lambda5-phosphane Chemical compound OP(O)(O)=S.S SUEGWIXYCHISPX-UHFFFAOYSA-N 0.000 description 4
229910052717 sulfur Inorganic materials 0.000 description 4
125000004434 sulfur atom Chemical group 0.000 description 4
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 3
102000004121 Annexin A5 Human genes 0.000 description 3
102000003952 Caspase 3 Human genes 0.000 description 3
230000006820 DNA synthesis Effects 0.000 description 3
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 3
241000282560 Macaca mulatta Species 0.000 description 3
241000282577 Pan troglodytes Species 0.000 description 3
210000001185 bone marrow Anatomy 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
208000029742 colonic neoplasm Diseases 0.000 description 3
230000021615 conjugation Effects 0.000 description 3
230000004069 differentiation Effects 0.000 description 3
230000010437 erythropoiesis Effects 0.000 description 3
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
230000001394 metastastic effect Effects 0.000 description 3
206010061289 metastatic neoplasm Diseases 0.000 description 3
230000035407 negative regulation of cell proliferation Effects 0.000 description 3
239000003921 oil Substances 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 3
102000003390 tumor necrosis factor Human genes 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
108090000672 Annexin A5 Proteins 0.000 description 2
208000011691 Burkitt lymphomas Diseases 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
108010077544 Chromatin Proteins 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
102000004533 Endonucleases Human genes 0.000 description 2
108010042407 Endonucleases Proteins 0.000 description 2
102000000588 Interleukin-2 Human genes 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
102000015696 Interleukins Human genes 0.000 description 2
108010063738 Interleukins Proteins 0.000 description 2
102000005741 Metalloproteases Human genes 0.000 description 2
108010006035 Metalloproteases Proteins 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
241000187481 Mycobacterium phlei Species 0.000 description 2
108091093105 Nuclear DNA Proteins 0.000 description 2
102000007999 Nuclear Proteins Human genes 0.000 description 2
108010089610 Nuclear Proteins Proteins 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
239000004365 Protease Substances 0.000 description 2
108010017842 Telomerase Proteins 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
239000003098 androgen Substances 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000027455 binding Effects 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
150000007942 carboxylates Chemical class 0.000 description 2
210000003855 cell nucleus Anatomy 0.000 description 2
230000010094 cellular senescence Effects 0.000 description 2
210000003483 chromatin Anatomy 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000001378 electrochemiluminescence detection Methods 0.000 description 2
239000000284 extract Substances 0.000 description 2
235000013861 fat-free Nutrition 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
230000019734 interleukin-12 production Effects 0.000 description 2
239000003446 ligand Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000006166 lysate Substances 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
235000013336 milk Nutrition 0.000 description 2
239000008267 milk Substances 0.000 description 2
210000004080 milk Anatomy 0.000 description 2
238000002156 mixing Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
229940055036 mycobacterium phlei Drugs 0.000 description 2
201000008968 osteosarcoma Diseases 0.000 description 2
230000037361 pathway Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000008569 process Effects 0.000 description 2
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
230000017854 proteolysis Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000028327 secretion Effects 0.000 description 2
PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
238000010186 staining Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
108091035539 telomere Proteins 0.000 description 2
102000055501 telomere Human genes 0.000 description 2
238000012360 testing method Methods 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
229960005486 vaccine Drugs 0.000 description 2
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
AOUOVFRSCMDPFA-QSDJMHMYSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(O)=O AOUOVFRSCMDPFA-QSDJMHMYSA-N 0.000 description 1
CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
YYYARFHFWYKNLF-UHFFFAOYSA-N 4-[(2,4-dimethylphenyl)diazenyl]-3-hydroxynaphthalene-2,7-disulfonic acid Chemical compound CC1=CC(C)=CC=C1N=NC1=C(O)C(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=C12 YYYARFHFWYKNLF-UHFFFAOYSA-N 0.000 description 1
102000015693 Actin Depolymerizing Factors Human genes 0.000 description 1
108010038798 Actin Depolymerizing Factors Proteins 0.000 description 1
208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
108020004491 Antisense DNA Proteins 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
102000004580 Aspartic Acid Proteases Human genes 0.000 description 1
108010017640 Aspartic Acid Proteases Proteins 0.000 description 1
238000011725 BALB/c mouse Methods 0.000 description 1
WTYQNWDZSGLSLW-UHFFFAOYSA-O CC1=CSC(C)=N1.C1=CC=CC=C1[NH+]1C(C=2C=CC=CC=2)=NN=N1 Chemical compound CC1=CSC(C)=N1.C1=CC=CC=C1[NH+]1C(C=2C=CC=CC=2)=NN=N1 WTYQNWDZSGLSLW-UHFFFAOYSA-O 0.000 description 1
101100005766 Caenorhabditis elegans cdf-1 gene Proteins 0.000 description 1
102000004041 Caspase 7 Human genes 0.000 description 1
102100035904 Caspase-1 Human genes 0.000 description 1
108090000426 Caspase-1 Proteins 0.000 description 1
102000004068 Caspase-10 Human genes 0.000 description 1
108090000572 Caspase-10 Proteins 0.000 description 1
102100032616 Caspase-2 Human genes 0.000 description 1
108090000552 Caspase-2 Proteins 0.000 description 1
102100025597 Caspase-4 Human genes 0.000 description 1
101710090338 Caspase-4 Proteins 0.000 description 1
102100038916 Caspase-5 Human genes 0.000 description 1
101710090333 Caspase-5 Proteins 0.000 description 1
102100026548 Caspase-8 Human genes 0.000 description 1
108090000538 Caspase-8 Proteins 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
206010057248 Cell death Diseases 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
230000005778 DNA damage Effects 0.000 description 1
231100000277 DNA damage Toxicity 0.000 description 1
230000012746 DNA damage checkpoint Effects 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
238000008157 ELISA kit Methods 0.000 description 1
102000010911 Enzyme Precursors Human genes 0.000 description 1
108010062466 Enzyme Precursors Proteins 0.000 description 1
102100031690 Erythroid transcription factor Human genes 0.000 description 1
101710100588 Erythroid transcription factor Proteins 0.000 description 1
108010040476 FITC-annexin A5 Proteins 0.000 description 1
230000010337 G2 phase Effects 0.000 description 1
230000004668 G2/M phase Effects 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
101000573199 Homo sapiens Protein PML Proteins 0.000 description 1
101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
102000049772 Interleukin-16 Human genes 0.000 description 1
101800003050 Interleukin-16 Proteins 0.000 description 1
102000006835 Lamins Human genes 0.000 description 1
108010047294 Lamins Proteins 0.000 description 1
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
102100021010 Nucleolin Human genes 0.000 description 1
XVZUMQAMCYSUMS-SIUGBPQLSA-N OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 XVZUMQAMCYSUMS-SIUGBPQLSA-N 0.000 description 1
239000002033 PVDF binder Substances 0.000 description 1
241000282579 Pan Species 0.000 description 1
241001494479 Pecora Species 0.000 description 1
101000708422 Podarcis siculus Tissue- and phase-specific nuclear protein Proteins 0.000 description 1
229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
230000006819 RNA synthesis Effects 0.000 description 1
101000933603 Rattus norvegicus Protein BTG1 Proteins 0.000 description 1
108700005075 Regulator Genes Proteins 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
238000011579 SCID mouse model Methods 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
230000005867 T cell response Effects 0.000 description 1
101710183280 Topoisomerase Proteins 0.000 description 1
102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
238000004115 adherent culture Methods 0.000 description 1
230000002411 adverse Effects 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
125000004103 aminoalkyl group Chemical group 0.000 description 1
230000003698 anagen phase Effects 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
230000001772 anti-angiogenic effect Effects 0.000 description 1
229940124650 anti-cancer therapies Drugs 0.000 description 1
238000011319 anticancer therapy Methods 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000003816 antisense DNA Substances 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
238000003782 apoptosis assay Methods 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
239000000022 bacteriostatic agent Substances 0.000 description 1
230000003385 bacteriostatic effect Effects 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000002798 bone marrow cell Anatomy 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
230000005907 cancer growth Effects 0.000 description 1
230000018486 cell cycle phase Effects 0.000 description 1
230000006369 cell cycle progression Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
108091092328 cellular RNA Proteins 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
239000003184 complementary RNA Substances 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000001461 cytolytic effect Effects 0.000 description 1
230000002435 cytoreductive effect Effects 0.000 description 1
210000004292 cytoskeleton Anatomy 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
230000000547 effect on apoptosis Effects 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000000925 erythroid effect Effects 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
230000005284 excitation Effects 0.000 description 1
239000000835 fiber Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
230000005251 gamma ray Effects 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
230000012010 growth Effects 0.000 description 1
102000054896 human PML Human genes 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000028993 immune response Effects 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
230000019189 interleukin-1 beta production Effects 0.000 description 1
230000031261 interleukin-10 production Effects 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
230000004068 intracellular signaling Effects 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
230000002601 intratumoral effect Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229920000831 ionic polymer Polymers 0.000 description 1
210000005053 lamin Anatomy 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
108010052968 leupeptin Proteins 0.000 description 1
125000005647 linker group Chemical group 0.000 description 1
238000011068 loading method Methods 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
210000005075 mammary gland Anatomy 0.000 description 1
238000005259 measurement Methods 0.000 description 1
210000003593 megakaryocyte Anatomy 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
239000004530 micro-emulsion Substances 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
230000004660 morphological change Effects 0.000 description 1
101150025333 murA gene Proteins 0.000 description 1
230000035772 mutation Effects 0.000 description 1
239000007908 nanoemulsion Substances 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
239000002077 nanosphere Substances 0.000 description 1
210000003928 nasal cavity Anatomy 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
229920005615 natural polymer Polymers 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
108010044762 nucleolin Proteins 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
125000003835 nucleoside group Chemical group 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000003651 pro-proliferative effect Effects 0.000 description 1
230000005522 programmed cell death Effects 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
208000016691 refractory malignant neoplasm Diseases 0.000 description 1
239000000523 sample Substances 0.000 description 1
230000009758 senescence Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229940035044 sorbitan monolaurate Drugs 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
229940063675 spermine Drugs 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
239000003277 telomerase inhibitor Substances 0.000 description 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
229940044693 topoisomerase inhibitor Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
108091006106 transcriptional activators Proteins 0.000 description 1
239000003656 tris buffered saline Substances 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
230000006433 tumor necrosis factor production Effects 0.000 description 1
102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
238000001262 western blot Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Plant Pathology (AREA)
Biochemistry (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Oncology (AREA)
Microbiology (AREA)
Hematology (AREA)
Communicable Diseases (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Saccharide Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

NO20022820A 1999-12-13 2002-06-13 Blanding bestaende av syntetisk fosfodiester-nukleotidsekvens og anvendelse derav. NO330508B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US17032599P	1999-12-13	1999-12-13
US22892500P	2000-08-29	2000-08-29
PCT/CA2000/001467 WO2001044465A2 (fr)	1999-12-13	2000-12-12	Oligonucleotides synthetiques utiles du point de vue therapeutique

Publications (3)

Publication Number	Publication Date
NO20022820D0 NO20022820D0 (no)	2002-06-13
NO20022820L NO20022820L (no)	2002-08-08
NO330508B1 true NO330508B1 (no)	2011-05-09

Family

ID=26865979

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20022820A NO330508B1 (no)	1999-12-13	2002-06-13	Blanding bestaende av syntetisk fosfodiester-nukleotidsekvens og anvendelse derav.

Country Status (18)

Country	Link
US (2)	US7157436B2 (fr)
EP (2)	EP1867718B1 (fr)
JP (1)	JP4772245B2 (fr)
KR (1)	KR100829646B1 (fr)
CN (2)	CN100445380C (fr)
AT (2)	ATE455851T1 (fr)
AU (1)	AU785212B2 (fr)
CA (1)	CA2393808A1 (fr)
CZ (1)	CZ20022372A3 (fr)
DE (2)	DE60036019T2 (fr)
DK (2)	DK1867718T3 (fr)
ES (2)	ES2340807T3 (fr)
HU (1)	HUP0300627A3 (fr)
IL (2)	IL150196A0 (fr)
MX (1)	MXPA02005842A (fr)
NO (1)	NO330508B1 (fr)
PT (1)	PT1238070E (fr)
WO (1)	WO2001044465A2 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030032610A1 (en)	1996-06-03	2003-02-13	Gilchrest Barbara A.	Method to inhibit cell growth using oligonucleotides
JP2002541264A (ja)	1999-04-08	2002-12-03	ユーエイビー・リサーチ・ファウンデーション	冨ｇオリゴヌクレオチドの抗増殖活性およびヌクレオリンに結合するためのその使用方法
US8114850B2 (en)	1999-04-08	2012-02-14	Advanced Cancer Therapeutics, Llc	Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US7960540B2 (en)	1999-04-08	2011-06-14	Advanced Cancer Therapeutics, Llc	Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US6949520B1 (en) *	1999-09-27	2005-09-27	Coley Pharmaceutical Group, Inc.	Methods related to immunostimulatory nucleic acid-induced interferon
WO2002018593A2 (fr)	2000-08-29	2002-03-07	Bioniche Life Sciences Inc.	Modulation de l'expression de fas et de fasl
EP1867718B1 (fr) *	1999-12-13	2010-01-20	Bioniche Life Sciences Inc.	Oligonucléotides synthétiques utiles du point de vue thérapeutique
ES2307568T3 (es) *	2000-12-08	2008-12-01	Coley Pharmaceutical Gmbh	Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
US7087586B2 (en) *	2001-04-24	2006-08-08	Bioniche Life Sciences, Inc.	Oligonucleotide compositions and their use to induce differentiation of cells
DK1417307T3 (da) *	2001-08-17	2009-07-13	Bioniche Life Sciences Inc	Oligonucleotidsammensætninger og deres anvendelse til at inducere apoptose
DE60208400T2 (de) *	2001-10-03	2006-07-06	Bioniche Life Sciences Inc., Belleville	Therapeutisch verwendbare triethylenglykol-cholesteryl-oligonukleotide
KR101092043B1 (ko)	2002-04-22	2011-12-12	바이오니취 라이프 사이언시즈 인코포레이티드	올리고뉴클레오티드 조성물 및 면역 반응 조절시 이의 용도
AU2004226605A1 (en) *	2003-04-02	2004-10-14	Coley Pharmaceutical Group, Ltd.	Immunostimulatory nucleic acid oil-in-water formulations for topical application
MXPA05012421A (es) *	2003-05-16	2006-02-22	Hybridon Inc	Tratamiento sinergistico de cancer usando inmunomeros junto con agentes quimioterapeuticos.
US20080009455A9 (en) *	2005-02-24	2008-01-10	Coley Pharmaceutical Group, Inc.	Immunostimulatory oligonucleotides
CA2600440A1 (fr) *	2005-03-09	2006-09-21	Baylor College Of Medicine	Inversion directe de la fonction inhibitrice des lymphocytes t regulateurs de cd4+ via la signalisation du recepteur 8 de type toll
US20090087456A1 (en) *	2005-09-07	2009-04-02	James Edward Eyles	Adjuvanted vaccine
CN102439149B (zh) *	2009-02-12	2018-01-02	库尔纳公司	通过抑制针对胶质细胞衍生神经营养因子(gdnf)的天然反义转录物来治疗gdnf相关的疾病
GB0906234D0 (en)	2009-04-14	2009-05-20	Secr Defence	Vaccine
KR100998365B1 (ko)	2009-06-29	2010-12-06	압타바이오 주식회사	치료 효능이 있는 변형핵산 및 구아노신을 함유하는 올리고뉴클레오티드 변형체
WO2011008305A1 (fr) *	2009-07-15	2011-01-20	Enzon Pharmaceuticals, Inc.	Antagoniste d'arn ciblant gli2 pour le traitement de la leucémie
EP2821504A4 (fr) *	2012-02-28	2016-02-17	Univ Tokyo Nat Univ Corp	Procédé permettant de désigner une maladie en relation avec la quantité de tdp-43 présent dans les cellules
EP4000597A1 (fr) *	2020-11-17	2022-05-25	The Boots Company plc	Tétrapeptide et compositions comprenant des tétrapeptides
KR20240126870A (ko)	2021-12-22	2024-08-21	캠프4 테라퓨틱스 코포레이션	조절 rna들을 표적으로 하는 안티센스 올리고뉴클레오티드를 사용한 유전자 전사의 조절

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3172815A (en) *	1962-04-24	1965-03-09	Warner Lambert Pharmaceutical	Method for preparing reticulo-endo-thelial system stimulant and stimulant thereof
US4152423A (en) *	1971-11-19	1979-05-01	Agence Nationale De Valorisation De La Recherche (Anvar)	Immunological agents
FR2160326B1 (fr) *	1971-11-19	1975-02-07	Anvar
CA1020460A (fr) *	1973-02-23	1977-11-08	Wellcome Foundation Limited (The)	Separation du glycopeptide immunostimulant des bacteries
US3976544A (en) *	1973-06-19	1976-08-24	The Agence Nationale De Valorisation De Le Recherche	Water-soluble immunological adjuvants, in particular for vaccines, obtained from mycobacteria and related microorganisms and process for their extraction
FR2374042A1 (fr) *	1976-06-04	1978-07-13	Merieux Inst	Nouveau medicament immunostimulant et son procede de preparation
JPS54140710A (en) *	1978-03-10	1979-11-01	Mitsui Toatsu Chem Inc	Anti-tumor substance and its preparation
DE3011461C2 (de) *	1980-03-25	1986-10-30	Dr. Madaus & Co, 5000 Köln	Verwendung von Propionibakterien
US4520019A (en) *	1982-04-29	1985-05-28	Ribi Immunochem Research, Inc.	Stable composition and preparation thereof
US4579941A (en) *	1982-08-13	1986-04-01	Mitsuitoatsu Chemicals, Inc.	Thermally-denatured deoxyribonucleic acid MD-011 and antitumor agent
US4663306A (en) *	1983-09-23	1987-05-05	Ribi Immunochem Research, Inc.	Pyridine-soluble extract-refined detoxified endotoxin composition and use
GB8404280D0 (en) *	1984-02-17	1984-03-21	Stanford J L	Biological preparations
DE3423234A1 (de) *	1984-06-23	1986-02-06	Boehringer Ingelheim International GmbH, 6507 Ingelheim	Synergistische mischungen von interferonen und tumor-nekrose-faktor
US4744984A (en) *	1985-10-08	1988-05-17	Vetrepharm Research, Inc.	Antiviral immunotherapeutic agent and preparation thereof
US4877611A (en) *	1986-04-15	1989-10-31	Ribi Immunochem Research Inc.	Vaccine containing tumor antigens and adjuvants
DE3723075A1 (de)	1987-07-11	1989-01-19	Boehringer Mannheim Gmbh	Eukaryotische expressionsvektoren mit multimeren enhancer-subelementen, verfahren zu ihrer herstellung und verwendung
US4958013A (en) *	1989-06-06	1990-09-18	Northwestern University	Cholesteryl modified oligonucleotides
CA1340994C (fr) *	1989-09-21	2000-05-16	Rudolf Edgar Dr. Falk	Traitement de maladies et d'etats pathologiques
WO1992007095A1 (fr) *	1990-10-15	1992-04-30	Stratagene	Procede de reaction en chaine de polymerase arbitrairement amorcee destine a produire une empreinte genetique de genomes
WO1992014842A1 (fr) *	1991-02-21	1992-09-03	Gilead Sciences, Inc.	Aptameres specifiques contre la thrombine et procedes d'utilisation
US6475795B1 (en) *	1991-07-03	2002-11-05	Meditech Research, Ltd.	Use of hyaluronan in gene therapy
US5582981A (en) *	1991-08-14	1996-12-10	Gilead Sciences, Inc.	Method for identifying an oligonucleotide aptamer specific for a target
US5474796A (en) *	1991-09-04	1995-12-12	Protogene Laboratories, Inc.	Method and apparatus for conducting an array of chemical reactions on a support surface
US5523389A (en) *	1992-09-29	1996-06-04	Isis Pharmaceuticals, Inc.	Inhibitors of human immunodeficiency virus
BR9406496A (pt) *	1993-01-29	1996-01-02	Vetrepharm Inc	Processo e composição para estimulação do sistema imunológico em um ser humano ou animal
US5567604A (en) *	1993-04-23	1996-10-22	Aronex Pharmaceuticals, Inc.	Anti-viral guanosine-rich oligonucleotides
CN1154702A (zh) *	1994-05-25	1997-07-16	海布里登公司	具有抗巨细胞病毒活性的寡核苷酸
DE69533037T2 (de) *	1994-08-30	2005-05-04	Commonwealth Scientific And Industrial Research Organisation	Pflanzentraskriptionsregulator von circovirus
US5643890A (en)	1995-01-31	1997-07-01	The Board Of Regents Of The University Of Nebraska	Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases
IN181358B (fr) *	1995-02-14	1998-05-30	Bioniche Inc
ZA964446B (en) *	1995-06-06	1996-12-06	Hoffmann La Roche	Oligonucleotides specific for hepatitis c virus
US5990299A (en) *	1995-08-14	1999-11-23	Icn Pharmaceuticals, Inc.	Control of CD44 gene expression for therapeutic use
CZ154898A3 (cs) *	1995-11-21	1998-09-16	Icn Pharmaceuticals, Inc.	Oligonukleotidy pro inhibici růstu nádorů zprostředkovaných IL-8 a receptorem IL-8
IT1277025B1 (it)	1995-12-04	1997-11-04	Cooperativa Centro Ricerche Po	Classe di oligonucleotidi fosfodiesterici ad attivita' citotossica composizioni farmaceutiche che li contengono e loro uso
US6015710A (en) *	1996-04-09	2000-01-18	The University Of Texas System	Modulation of mammalian telomerase by peptide nucleic acids
EP1011729B1 (fr) *	1996-05-20	2008-01-09	THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES	Oligonucleotides qui lient specifiquement des proteines nucleocapsidiques retrovirales
KR100533576B1 (ko) *	1997-08-05	2005-12-05	바이오니취 라이프 사이언시즈 인코포레이티드	세포증식 및 세포사멸 조절용 조성물 및 방법
US6255473B1 (en) *	1997-08-29	2001-07-03	Duke University	Presenilin-1 gene promoter
NZ517929A (en) *	1999-09-25	2004-02-27	Univ Iowa Res Found	Immunostimulatory nucleic acids
EP1867718B1 (fr) *	1999-12-13	2010-01-20	Bioniche Life Sciences Inc.	Oligonucléotides synthétiques utiles du point de vue thérapeutique
US20020091095A1 (en) *	1999-12-13	2002-07-11	Phillips Nigel C.	Modulation of Fas and FasL expression
CA2395493C (fr) *	1999-12-28	2010-06-22	Bioniche Life Sciences Inc.	L'acide hyaluronique dans le traitement du cancer
DE60208400T2 (de) *	2001-10-03	2006-07-06	Bioniche Life Sciences Inc., Belleville	Therapeutisch verwendbare triethylenglykol-cholesteryl-oligonukleotide
KR101092043B1 (ko) *	2002-04-22	2011-12-12	바이오니취 라이프 사이언시즈 인코포레이티드	올리고뉴클레오티드 조성물 및 면역 반응 조절시 이의 용도

2000
- 2000-12-12 EP EP07015976A patent/EP1867718B1/fr not_active Expired - Lifetime
- 2000-12-12 IL IL15019600A patent/IL150196A0/xx unknown
- 2000-12-12 CZ CZ20022372A patent/CZ20022372A3/cs unknown
- 2000-12-12 DE DE60036019T patent/DE60036019T2/de not_active Expired - Lifetime
- 2000-12-12 KR KR1020027007557A patent/KR100829646B1/ko not_active Expired - Fee Related
- 2000-12-12 HU HU0300627A patent/HUP0300627A3/hu unknown
- 2000-12-12 AU AU18479/01A patent/AU785212B2/en not_active Ceased
- 2000-12-12 MX MXPA02005842A patent/MXPA02005842A/es active IP Right Grant
- 2000-12-12 CA CA002393808A patent/CA2393808A1/fr not_active Abandoned
- 2000-12-12 DE DE60043759T patent/DE60043759D1/de not_active Expired - Lifetime
- 2000-12-12 ES ES07015976T patent/ES2340807T3/es not_active Expired - Lifetime
- 2000-12-12 US US09/735,363 patent/US7157436B2/en not_active Expired - Fee Related
- 2000-12-12 AT AT07015976T patent/ATE455851T1/de not_active IP Right Cessation
- 2000-12-12 CN CNB008188580A patent/CN100445380C/zh not_active Expired - Fee Related
- 2000-12-12 DK DK07015976.9T patent/DK1867718T3/da active
- 2000-12-12 EP EP00981117A patent/EP1238070B1/fr not_active Expired - Lifetime
- 2000-12-12 WO PCT/CA2000/001467 patent/WO2001044465A2/fr not_active Ceased
- 2000-12-12 CN CN2008101740188A patent/CN101491536B/zh not_active Expired - Fee Related
- 2000-12-12 DK DK00981117T patent/DK1238070T3/da active
- 2000-12-12 PT PT00981117T patent/PT1238070E/pt unknown
- 2000-12-12 JP JP2001545542A patent/JP4772245B2/ja not_active Expired - Fee Related
- 2000-12-12 AT AT00981117T patent/ATE370231T1/de active
- 2000-12-12 ES ES00981117T patent/ES2288883T3/es not_active Expired - Lifetime
2002
- 2002-06-12 IL IL150196A patent/IL150196A/en not_active IP Right Cessation
- 2002-06-13 NO NO20022820A patent/NO330508B1/no not_active IP Right Cessation
2006
- 2006-12-18 US US11/641,542 patent/US20070213291A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20070213291A1 (en)	2007-09-13
EP1867718A3 (fr)	2008-04-02
WO2001044465A3 (fr)	2001-11-29
AU785212B2 (en)	2006-11-09
WO2001044465A2 (fr)	2001-06-21
US7157436B2 (en)	2007-01-02
ES2340807T3 (es)	2010-06-09
CN101491536A (zh)	2009-07-29
CA2393808A1 (fr)	2001-06-21
EP1238070B1 (fr)	2007-08-15
US20010041681A1 (en)	2001-11-15
EP1238070A2 (fr)	2002-09-11
NO20022820L (no)	2002-08-08
EP1867718A2 (fr)	2007-12-19
DK1867718T3 (da)	2010-04-12
CZ20022372A3 (cs)	2002-11-13
NO20022820D0 (no)	2002-06-13
KR20020079752A (ko)	2002-10-19
CN1433469A (zh)	2003-07-30
KR100829646B1 (ko)	2008-05-16
JP2003517041A (ja)	2003-05-20
ATE370231T1 (de)	2007-09-15
DE60036019D1 (de)	2007-09-27
HUP0300627A3 (en)	2005-11-28
MXPA02005842A (es)	2003-10-14
AU1847901A (en)	2001-06-25
HUP0300627A2 (hu)	2004-06-28
JP4772245B2 (ja)	2011-09-14
DE60043759D1 (de)	2010-03-11
DE60036019T2 (de)	2008-05-29
DK1238070T3 (da)	2007-12-03
CN101491536B (zh)	2012-07-04
PT1238070E (pt)	2007-11-06
CN100445380C (zh)	2008-12-24
EP1867718B1 (fr)	2010-01-20
IL150196A (en)	2009-06-15
IL150196A0 (en)	2002-12-01
ATE455851T1 (de)	2010-02-15
ES2288883T3 (es)	2008-02-01

Legal Events

Date	Code	Title	Description
2014-07-21	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO330508B1 (no)	2011-05-09	Blanding bestaende av syntetisk fosfodiester-nukleotidsekvens og anvendelse derav.
ES2543710T3 (es)	2015-08-21	Oligorribonucleótidos inmunoestimulantes que contienen G y U
US7935351B2 (en)	2011-05-03	Use of CPG oligodeoxynucleotides to induce angiogenesis
CN112105733B (zh)	2024-10-29	合成rig-i样受体激动剂
Gray et al.	2007	CpG-B ODNs potently induce low levels of IFN-αβ and induce IFN-αβ-dependent MHC-I cross-presentation in DCs as effectively as CpG-A and CpG-C ODNs
Rayburn et al.	2007	Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53
US20020091095A1 (en)	2002-07-11	Modulation of Fas and FasL expression
KR101017483B1 (ko)	2011-02-25	올리고뉴클레오타이드 조성물 및 세포사멸을 유도하기위한 그의 용도
Kuramoto et al.	2006	Inhibition of peritoneal dissemination of tumor cells by single dosing of phosphodiester CpG oligonucleotide/cationic liposome complex
Mohri et al.	2012	Increased immunostimulatory activity of polypod-like structured DNA by ligation of the terminal loop structures
AU2007200536A1 (en)	2007-03-01	Therapeutically useful synthetic oligonucleotides
Erhardt et al.	2005	Transfection of human monocyte‐derived dendritic cells with CpG oligonucleotides
ES2383671T3 (es)	2012-06-25	Modulación de la expresión de Fas y FasL por un oligonucleótido-fosfodiéster sintético y un anticuerpo anti-Fas
HK1133388A (en)	2010-03-26	Therapeutically useful synthetic oligonucleotides
AU2001268863B2 (en)	2007-07-05	Modulation of FAS and FASL expression
CA2420103A1 (fr)	2002-03-07	Modulation de l'expression de fas et de fasl
AU2001268863A1 (en)	2002-06-06	Modulation of FAS and FASL expression
AU2001268863A2 (en)	2003-07-17	Modulation of FAS and FASL expression
EP1313853A2 (fr)	2003-05-28	Modulation de l'expression de fas et de fasl